The final, formatted version of the article will be published soon.You have multiple emails registered with Frontiers:Please enter your email address:

。您在Frontiers注册了多封电子邮件：请输入您的电子邮件地址：

If you already have an account, please

如果您已经有账户，请

login

登录名

You don't have a Frontiers account ? You can

你没有Frontiers帐户？你可以

register hereBackground: To investigate the relationship between the Scottish inflammatory prognostic score (SIPS), treatment-related adverse events (TRAEs), and prognostication in patients with neoadjuvant immunochemotherapy (NICT) for esophageal squamous cell carcinoma (ESCC).Methods: A retrospective investigation was carried out on 208 ESCC patients treated with NICT.

背景：调查苏格兰炎症预后评分（SIPS），治疗相关不良事件（TRAEs）与食管鳞状细胞癌（ESCC）新辅助免疫化疗（NICT）患者预后之间的关系。方法：对208例接受NICT治疗的ESCC患者进行回顾性调查。

The relationships between the SIPS, TRAEs, and prognosis [disease-free survival (DFS) and overall survival (OS)] were analyzed.The patients, comprising 62 (29.8%) cases of SIPS0, 103 (49.5%) cases of SIPS1, and 43 (20.7%) cases of SIPS2, were categorized into three groups based on SIPS. Pathological complete response (PCR) rates showed statistically significant variations between the three groups (SIPS0: 45.2%, SIPS1: 27.2%, SIPS2: 16.3%, P=0.004).

分析SIPS，TRAEs与预后[无病生存期（DFS）和总生存期（OS）]之间的关系。这些患者包括62例（29.8%）SIPS0，103例（49.5%）SIPS1和43例（20.7%）SIPS2，根据SIPS分为三组。病理完全缓解（PCR）率显示三组之间存在统计学显着差异（SIPS0:45.2%，SIPS1:27.2%，SIPS2:16.3%，P=0.004）。

All TRAEs were found in 63.9% (133 cases) of the cases, with serious TRAEs (grade 3-4) accounting for 13.9% (29 cases).TRAEs themselves were not linked with SIPS (P=0.668), while serious TRAEs had a significant correlation with SIPS (P=0.002). Multivariate logistic analysis showed that SIPS2 seemed to confer serious TRAEs [odds radio (OR)=4.044; 95% CI: 1.395-11.722; P=0.010].

所有TRAE均在63.9%（133例）的病例中发现，严重TRAE（3-4级）占13.9%（29例）。TRAE本身与SIPS无关（P=0.668），而严重TRAE与SIPS有显着相关性（P=0.002）。多因素logistic分析显示，SIPS2似乎赋予严重的TRAE[赔率比（OR）=4.044；95%CI:1.395-11.722；P=0.010]。

For patients classified as SIPS0, 1, or 2, the 3-year DFS was 83.9%, 58.3%, and 39.5% (P<0.001). The 3-year OS for those with SIPS0, 1, or 2 was 88.7%, 72.8%, and 53.5%, respectively (P<0.001).SIPS was substantially correlated with DFS (but not with OS) and could be utilized as an independent predictor [SIPS2: hazard ratio (HR)=3.743, 95% CI: 1.770-7.914, P=0.001; SIPS1: HR=2.303, 95% CI: 1.149-4.616, P=0.019].The SIPS is associated with serious TRAEs and can be used as a predictor of serious TRAEs in ESCC receiving NICT..

。SIPS0、1或2患者的3年OS分别为88.7%、72.8%和53.5%（P＜0.001）。SIPS与DFS显着相关（但与OS无关），可作为独立预测因子[SIPS2：危险比（HR）=3.743，95%CI:1.770-7.914，P=0.001；SIPS1：HR=2.303，95%CI:1.149-4.616，P=0.019]。SIPS与严重TRAE相关，可作为ESCC接受NICT的严重TRAE的预测指标。。